Skip to main content

H.C. Wainwright Sticks to Its Buy Rating for Mind Medicine (MNMD)

Tipranks - Tipranks - Wed Nov 12, 2025

In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Mind Medicine, with a price target of $55.00.

Meet Your ETF AI Analyst

Trucchio covers the Healthcare sector, focusing on stocks such as Aligos Therapeutics, Altimmune, and Precision BioSciences. According to TipRanks, Trucchio has an average return of 34.8% and a 52.26% success rate on recommended stocks.

Currently, the analyst consensus on Mind Medicine is a Strong Buy with an average price target of $29.71.

See today’s best-performing stocks on TipRanks >>

Based on Mind Medicine’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $67.27 million. In comparison, last year the company had a GAAP net loss of $13.68 million

Read More on MNMD:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).